961 related articles for article (PubMed ID: 26930401)
1. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
2. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
Yue Y; Cui X; Bose S; Audeh W; Zhang X; Fraass B
Breast Cancer Res Treat; 2015 Oct; 153(3):607-16. PubMed ID: 26346756
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
Zuo T; Wilson P; Cicek AF; Harigopal M
Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
6. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological features of metaplastic breast carcinoma.
Hasdemir OA; Tokgöz S; Köybaşıoğlu F; Karabacak H; Yücesoy C; İmamoğlu Gİ
Adv Clin Exp Med; 2018 Apr; 27(4):509-513. PubMed ID: 29558027
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
11. Prognostic markers in triple-negative breast cancer.
Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO
Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
13. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
[TBL] [Abstract][Full Text] [Related]
14. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
Peng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features of triple-negative breast cancer in Taiwanese women.
Yao-Lung K; Dar-Ren C; Tsai-Wang C
Int J Clin Oncol; 2011 Oct; 16(5):500-5. PubMed ID: 21455625
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
18. Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.
Schmidt G; Meyberg-Solomayer G; Gerlinger C; Juhasz-Böss I; Herr D; Rody A; Liedtke C; Solomayer EF
Arch Gynecol Obstet; 2014 Dec; 290(6):1221-9. PubMed ID: 25012601
[TBL] [Abstract][Full Text] [Related]
19. Validation of the Prognostic Significance of the Prognostic Stage Group According to the Eighth Edition of American Cancer Joint Committee on Cancer Staging System in Triple-Negative Breast Cancer: An Analysis From Surveillance, Epidemiology, and End Results 18 Database.
Luo SP; Wu QS; Chen H; Wang XX; Chen QX; Zhang J; Song CG
J Surg Res; 2020 Mar; 247():211-219. PubMed ID: 31706539
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.
Cubukcu E; Kanat O; Fatih Olmez O; Kabul S; Canhoroz M; Avci N; Deligonul A; Hartavi M; Cubukcu S; Olmez F; Kurt E; Evrensel T; Gokgoz S; Manavoglu O
J BUON; 2013; 18(2):359-65. PubMed ID: 23818346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]